NAGE — Niagen Bioscience Share Price
0.000.00%
Last trade - 00:00- $350.75m
- $286.12m
- $129.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.02 | ||
| PEG Ratio (f) | 0.51 | ||
| EPS Growth (f) | 42.29% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.58 | ||
| Price to Tang. Book | 4.95 | ||
| Price to Free Cashflow | 26.55 | ||
| Price to Sales | 2.71 | ||
| EV to EBITDA | 16.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.82% | ||
| Return on Equity | 28.35% | ||
| Operating Margin | 12.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 67.45 | 72.05 | 83.57 | 99.6 | 129.42 | 147.83 | 169.38 | 16.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +65.63 | +50.6 | +26.37 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Directors
- Frank Jaksch CHM (52)
- Robert Fried CEO (61)
- Kevin Farr CFO (63)
- Fadi Karam CMO
- Lisa Harrington GCN (53)
- Kurt Gustafson LED (53)
- Jeffrey Baxter IND (59)
- Stephen Block IND (76)
- Caroline Levy IND (58)
- Gary Ng IND (49)
- Steven Rubin IND (61)
- Wendy Yu IND (45)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- June 19th, 2008
- Public Since
- June 25th, 2007
- No. of Shareholders
- 30
- No. of Employees
- 117
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 80,080,488
- Address
- 10900 Wilshire Blvd Suite 600, LOS ANGELES, 90024
- Web
- https://www.niagenbioscience.com/
- Phone
- +1 3103886706
- Auditors
- Crowe LLP
Upcoming Events for NAGE
Niagen Bioscience Inc Annual Shareholders Meeting
Q2 2026 Niagen Bioscience Inc Earnings Release
Similar to NAGE
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Niagen Bioscience share price?
As of Today at 13:18 UTC, shares in Niagen Bioscience are trading at $4.38. This share price information is delayed by 15 minutes.
How has the Niagen Bioscience share price performed this year?
Shares in Niagen Bioscience last closed at $4.38 and the price had moved by -38.14% over the past 365 days. In terms of relative price strength the Niagen Bioscience share price has underperformed the S&P500 Index by -52.31% over the past year.
What are the analyst and broker recommendations for Niagen Bioscience?
The overall consensus recommendation for Niagen Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Niagen Bioscience dividend yield?
Niagen Bioscience does not currently pay a dividend.
Does Niagen Bioscience pay a dividend?
Niagen Bioscience does not currently pay a dividend.
When does Niagen Bioscience next pay dividends?
Niagen Bioscience does not currently pay a dividend.
How do I buy Niagen Bioscience shares?
To buy shares in Niagen Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Niagen Bioscience?
As of the previous close price of $4.38, shares in Niagen Bioscience had a market capitalisation of $350.75m.
Where are Niagen Bioscience shares listed?
Here are the trading details for Niagen Bioscience:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NAGE
What kind of share is Niagen Bioscience?
Based on an overall assessment of its quality, value and momentum Niagen Bioscience is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Niagen Bioscience share price forecast for 2026?
The analyst consensus target price for shares in Niagen Bioscience is $13.60. That is 210.5% above the last closing price of $4.38.
Analysts covering Niagen Bioscience currently have a consensus Earnings Per Share (EPS) forecast of $0.27 for the next financial year.
Find out moreWhat is the trend in the Niagen Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Niagen Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -35.28%.
As of the last closing price of $4.38, shares in Niagen Bioscience were trading -43.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Niagen Bioscience PE Ratio?
The Niagen Bioscience PE ratio based on its reported earnings over the past 12 months is 15.02. The shares last closed at $4.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Niagen Bioscience?
Niagen Bioscience's management team is headed by:
- Frank Jaksch - CHM
- Robert Fried - CEO
- Kevin Farr - CFO
- Fadi Karam - CMO
- Lisa Harrington - GCN
- Kurt Gustafson - LED
- Jeffrey Baxter - IND
- Stephen Block - IND
- Caroline Levy - IND
- Gary Ng - IND
- Steven Rubin - IND
- Wendy Yu - IND